skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Bcr-Abl (b2a2)-Derived Peptide Vaccine (Code C61309)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Bcr-Abl (b2a2)-Derived Peptide Vaccine

Definition: A peptide vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. Fusion genes in CML typically result from the fusion of either BCR exon b2 or BCR exon b3 to ABL exon a2, a 'b3a2' or a 'b2a2' fusion.

Display Name: Bcr-Abl (b2a2)-Derived Peptide Vaccine

Label: Bcr-Abl (b2a2)-Derived Peptide Vaccine

NCI Thesaurus Code: C61309 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831816  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Bcr-Abl (b2a2)-Derived Peptide Vaccine
CML-VAX B2

External Source Codes: 
PDQ Closed Trial Search ID 484895
PDQ Open Trial Search ID 484895 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831816

Other Properties:
     Name Value (qualifiers indented underneath)
code C61309
Contributing_Source CTRP
Legacy_Concept_Name Bcr-Abl_b2a2_Derived_Peptide_Vaccine
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61309

Mainbox Bottom